Get started
Author

Adelaida La Casta

Observed names: A. La Casta, A. La Casta Muñoa, A. Lacasta, Adelaida La Casta Munoa, Adelaida La Casta Muñoa, Adelaida La La Casta, Adelaida Lacasta
Observed institutions: University of the Basque Country, Instituto de Salud Carlos III, Hospital de Sant Pau, Biogipuzkoa Health Research Institute, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Donostiako Unibertsitate Ospitalea, Onkologikoa
ORCID: 0000-0002-7235-6378
Observed ORCID: 0000-0002-7235-6378
OpenAlex ID: A5027307341
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
2022 · Laura Izquierdo-Sanchez, Angela Lamarca, et al. · Journal of Hepatology · 352
PDF
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
2017 · Ander Arbelaiz, Mikel Azkargorta, et al. · Hepatology · 289
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
2012 · Eduardo Díaz-Rubio, Auxiliadora Gómez-España, et al. · The Oncologist · 210
PDF
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
2023 · Ainhoa Lapitz, Mikel Azkargorta, et al. · Journal of Hepatology · 185
PDF
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis
2018 · Jesus M. Banales, Mercedes Iñarrairaegui, et al. · Hepatology · 179
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
2020 · Aitor Esparza-Baquer, Ibone Labiano, et al. · Gut · 125
PDF
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
2021 · Jaume Capdevila, Nicola Fazio, et al. · Journal of Clinical Oncology · 116
PDF
SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma
2017 · Maite Merino-Azpitarte, Elisa Lozano, et al. · Journal of Hepatology · 105
PDF
Medical treatment for cholangiocarcinoma
2019 · Jorge Adeva, Bruno Sangro, et al. · Liver International · 96
Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis
2020 · Ainhoa Lapitz, Ander Arbelaiz, et al. · Cells · 94
PDF
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2
2018 · Teresa Macarulla, Roberto Pazo-Cid, et al. · Journal of Clinical Oncology · 94
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
2019 · Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, et al. · Journal of Clinical Oncology · 79
Biliary tract cancers: SEOM clinical guidelines
2015 · M. Benavides, A. Antón, et al. · Clinical & Translational Oncology · 78
PDF
Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System
2020 · Angela Lamarca, Alvaro Santos‐Laso, et al. · Hepatology · 75
PDF
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
2020 · José J. G. Marin, Maria Giuseppina Prete, et al. · British Journal of Cancer · 59
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
2020 · Enrique Aranda, Jose Maria Viéitez, et al. · ESMO Open · 58
PDF
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
2020 · Enrique Grande, Alex Teulé, et al. · The Oncologist · 41
PDF
Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry
2022 · Lynn E. Nooijen, Jesus M. Banales, et al. · Cancers · 37
PDF
A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma
2020 · Rocio I. R. Macias, Luis Muñoz-Bellvís, et al. · Cancers · 35
PDF
Association between EGFR gene polymorphisms, skin rash and response to anti‐ EGFR therapy in metastatic colorectal cancer patients
2014 · Ane Jaka, Araika Gutiérrez‐Rivera, et al. · Experimental Dermatology · 21
PDF
Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease
2024 · Anne-Marleen van Keulen, Stefan Buettner, et al. · Annals of Surgical Oncology · 15
PDF
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
2018 · Paula Jiménez-Fonseca, Miguel Navarro Martín, et al. · Oncotarget · 14
PDF
Targeting protein hyper-SUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma cross talk
2025 · Paula Olaizola, Irene Olaizola, et al. · Hepatology · 12
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
2021 · Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, et al. · Neuroendocrinology · 12
PDF
Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen
2012 · Carlos Gómez-Martin, Antonio Sánchez, et al. · Clinical & Translational Oncology · 12
Works count: 61
Citation count: 2,477
H-index: 20
I10-index: 28
Year
Topic
Type